Development of LC/MS/MS, high-throughput enzymatic and cellular assays for the characterization of compounds that inhibit kynurenine monooxygenase (KMO)

Journal of Biomolecular Screening

Volumn 18, Issue 8, 2013, Pages 879-889

  Winkler, Dirk ^a   Beconi, Maria ^b   Toledo Sherman, Leticia M ^b   Prime, Michael ^c   Ebneth, Andreas ^a   Dominguez, Celia ^b   Muñoz Sanjuan, Ignacio ^b  

^a EVOTEC AG   (Germany)

^b CHDI MANAGEMENT CHDI FOUNDATION   (United States)

^c EVOTEC UK LTD   (United Kingdom)

Author keywords

3 hydroxykynurenine; human PBMCs; kynurenine; kynurenine 3 monooxygenase; LC MS MS; microglia

Indexed keywords

3 HYDROXYKYNURENINE; 3,4 DIMETHOXY N [4 (3 NITROPHENYL) 2 THIAZOLYL]BENZENESULFONAMIDE; CELL AND TISSUE EXTRACTS; ENZYME INHIBITOR; FCE 28833; KYNURENINE; KYNURENINE MONOOXYGENASE; UNCLASSIFIED DRUG; UNSPECIFIC MONOOXYGENASE; UPF 648;

ANIMAL CELL; ARTICLE; CELL ASSAY; COMPETITIVE INHIBITION; CONTROLLED STUDY; ENZYMATIC ASSAY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IMMUNOFLUORESCENCE; INCUBATION TIME; LIQUID CHROMATOGRAPHY; MICROGLIA; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROTEIN STABILITY; RAT; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; WESTERN BLOTTING;

3-HYDROXYKYNURENINE; HUMAN PBMCS; KYNURENINE; KYNURENINE 3-MONOOXYGENASE; LC/MS/MS; MICROGLIA;

ANIMALS; CELL LINE; CHO CELLS; CHROMATOGRAPHY, LIQUID; CRICETULUS; DOGS; DRUG DISCOVERY; ENZYME ASSAYS; HEK293 CELLS; HUMANS; HUNTINGTON DISEASE; KYNURENINE; KYNURENINE 3-MONOOXYGENASE; LEUKOCYTES, MONONUCLEAR; MACACA FASCICULARIS; MICE; MICE, INBRED C57BL; RATS; RATS, WISTAR; TANDEM MASS SPECTROMETRY;

EID: 84882340209     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057113489731     Document Type: Article

References (30)

1. Reiner A., Dragatsis I., Dietrich P.. Genetics and Neuropathology of Huntington's Disease. Int. Rev. Neurobiol. 2011 ; 98: 325-372
2. Novak M. J. U., Tabrizi S. J.. Huntington's Disease: Clinical Presentation and Treatment. Int. Rev. Neurobiol. 2011 ; 98: 297-323
3. Schwarcz R., Bruno J. P., Muchowski P. J., et al. Kynurenines in the Mammalian Brain: When Physiology Meets Pathology. Nat. Rev. Neurosci. 2012 ; 13: 465-477
4. Thevandavakkam M. A., Schwarcz R., Muchowski P. J., et al. Targeting Kynurenine 3-Monooxygenase (KMO): Implications for Therapy in Huntington's Disease. CNS Neurol. Disord. Drug Targets. 2010 ; 9: 791-800
5. Giorgini F., Möller T., Kwan W., et al. Histone Deacetylase Inhibition Modulates Kynurenine Pathway Activation in Yeast, Microglia, and Mice Expressing a Mutant huntingtin Fragment. J. Biol. Chem. 2008 ; 283: 7390-7400
6. Guidetti P., Bates G. P., Graham R. K., et al. Elevated Brain 3-Hydroxykynurenine and Quinolinate Levels in Huntington Disease Mice. Neurobiol. Dis. 2006 ; 23: 190-197
7. Moroni F., Cozzi A., Sili M., et al. Kynurenic Acid: A Metabolite with Multiple Actions and Multiple Targets in Brain and Periphery. J. Neural Transm. 2012 ; 119: 133-139
8. Giorgini F., Guidetti P., Nguyen Q., et al. A Genomic Screen in Yeast Implicates Kynurenine 3-Monooxygenase as a Therapeutic Target for Huntington Disease. Nat. Genet. 2005 ; 37: 526-531
9. Zwilling D., Huang S. Y., Sathyasaikumar K. V., et al. Kynurenine 3-Monooxygenase Inhibition in Blood Ameliorates Neurodegeneration. Cell. 2011 ; 145: 863-874
10. Greis M. P.. Mass Spectrometry for Enzyme Assays and Inhibitor Screening: An Emerging Application in Pharmaceutical Research. Mass Spectrom. Rev. 2007 ; 26: 324-339
11. Liesener A., Karst U.. Monitoring Enzymatic Conversions by Mass Spectrometry: A Critical Review. Anal. Bioanal. Chem. 2005 ; 382: 1451-1464
12. Copeland R. A.. Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists. Methods Biochem. Anal. 2005 ; 46: 1-265
13. Rossi F., Valentina C., Garavaglia S., et al. Crystal Structure-Based Selective Targeting of the Pyridoxal 5′-Phosphate Dependent Enzyme Kynurenine Aminotransferase II for Cognitive Enhancement. J. Med. Chem. 2010 ; 53: 5684-5689
14. Han Q., Cai T., Tagle D. A., et al. Thermal Stability, pH Dependence and Inhibition of Four Murine Kynurenine Aminotransferases. BMC Biochem. 2010 ; 19: 11-19
15. Théry C., Chamak B., Mallat M.. Cytotoxic Effect of Brain Macrophages on Developing. Eur. J. Neurosci. 2006 ; 26: 3345-3356
16. Dobbertin A., Schmid P., Gelman M., et al. Neurons Promote Macrophage Proliferation by Producing Transforming Growth Factor-beta2. J. Neurosci. 1997 ; 17: 5305-5315
17. Saito Y., Hayashi O., Rothberg S.. Studies on Oxygenases; Enzymatic Formation of 3-Hydroxy-L-kynurenine from L-kynurenine. J. Biol. Chem. 1957 ; 229: 921-934
18. Röver S., Cesura A. M., Huguenin P., et al. Synthesis and Biochemical Evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as High-Affinity Inhibitors of Kynurenine 3-Hydroxylase. J. Med. Chem. 1997 ; 40: 4378-4385
19. Amori L., Guidetti P., Pellicciari R., et al. On the Relationship between the Two Branches of the Kynurenine Pathway in the Rat Brain In Vivo. J. Neurochem. 2009 ; 109: 316-325
20. Speciale C., Cini M., Wu H. Q., et al. Kynurenic Acid-Enhancing and Anti-ischemic Effects of the Potent Kynurenine 3-Hydroxylase Inhibitor FCE 28833 in Rodents. Adv. Exp. Med. Biol. 1996 ; 398: 221-227
21. Kakkar T., Boxenbaum H., Mayersohn M.. Estimation of Ki in a Competitive Enzyme-Inhibition Model: Comparisons among Three Methods of Data Analysis. Drug Metab. Dispos. 1999 ; 27: 756-762
22. Saito K., Chen C. Y., Masana M., et al. 4-Chloro-3-hydroxyanthranilate, 6-Chlorotryptophan and Norharmane Attenuate Quinolinic Acid Formation by Interferon-gamma-Stimulated Monocytes (THP-1 Cells). Biochem. J. 1993 ; 291 (Pt 1). 11-14
23. Chiarugi A., Calvani M., Meli E., et al. Synthesis and Release of Neurotoxic Kynurenine Metabolites by Human Monocyte-Derived Macrophages. J. Neuroimmunol. 2001 ; 120: 190-198
24. Connor T. J., Starr N., O'Sullivan J. B., et al. Induction of Indolamine 2,3-Dioxygenase and Kynurenine 3-Monooxygenase in Rat Brain following a Systemic Inflammatory Challenge: A Role for IFN-gamma?. Neurosci. Lett. 2008 ; 441: 29-34
25. Dikalov S. I., Li W., Doughan A. K., et al. Mitochondrial Reactive Oxygen Species and Calcium Uptake Regulate Activation of Phagocytic NADPH Oxidase. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2012 ; 302: 1134-1142
26. Crucian B., Dunne P., Friedman H., et al. Alterations in Peripheral Blood Mononuclear Cell Cytokine Production in Response to Phytohemagglutinin in Multiple Sclerosis Patients. Clin. Diagn. Lab. Immunol. 1995 ; 2: 766-769
27. Heyes M. P., Chen C. Y., Major E. O., et al. Different Kynurenine Pathway Enzymes Limit Quinolinic Acid Formation by Various Human Cell Types. Biochem. J. 1997 ; 326 (Pt 2). 351-356
28. Saito K., Quearry B. J., Saito M., et al. Kynurenine 3-Hydroxylase in Brain: Species Activity Differences and Effect of Gerbil Cerebral Ischemia. Arch. Biochem. Biophys. 1993 ; 307: 104-109
29. Breton J., Avanzi N., Magagnin S., et al. Functional Characterization and Mechanism of Action of Recombinant Human Kynurenine 3-Hydroxylase. Eur. J. Biochem. 2000 ; 267: 1092-1099
30. Alberati-Giani D., Cesura A. M.. Expression of the Kynurenine Enzymes in Macrophages and Microglial Cells: Regulation by Immune Modulators. Amino Acids. 1998 ; 14: 251-255